

ASSIGNMENT

WHEREAS, the undersigned, hereinafter referred to collectively as Assignor, has invented:

IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY

for which Assignor is about to make or has made United States or International application for patent

- (a) ☐ executed on even date preparatory to filing (each inventor should sign this Assignment on the same day as he/she signs the Declaration and Power of Attorney);
- (b) ☐ executed on _____, _____, _____; or
- (c) ☒ filed on **October 13, 2023**, and assigned PCT Application No. **PCT/CN2023/124461**; and

WHEREAS, **BeiGene Switzerland GmbH**, having the address of Aeschengraben 27, 4051 Basel, Switzerland, hereinafter referred to as Assignee, is desirous of acquiring all right, title, and interest therein:

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy whereof is hereby acknowledged, Assignor hereby confirms any prior assignment to Assignee, and to the extent that Assignor has not already done so, agrees to assign, and hereby does, sell, assign and transfer unto Assignee and its successors in interest, the full and exclusive right, title and interest in the United States of America and throughout the world, including the right to claim priority under the laws of the United States, the Paris Convention, and any foreign countries, to the inventions as described in the aforesaid application, to the aforesaid application itself, and all divisions, continuations, continuations-in-part, or other applications claiming priority directly or indirectly from the aforesaid application, and any United States or foreign Letters Patent, utility model, or other similar rights which may be granted thereon, including reissues, reexaminations and extensions thereof, and all copyright rights throughout the world in the aforesaid application and the subject matter disclosed therein, these rights, title and interest to be held and enjoyed by Assignee to the full end of the term for which the Letters Patent, utility model, or other similar rights, are granted and any extensions thereof as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made, and the right to sue for, and recover for past infringements of, or liabilities for, any of the rights relating to any of the applications, patents, utility models, or other similar rights, resulting therefrom, and the copyright rights;

Assignor hereby covenants and agrees to execute all instruments or documents required or requested for the making and prosecution of any applications of any type for patent, utility model, or other similar rights, and for copyright, in the United States and in all foreign countries including, but not limited to, any provisional, continuation, continuation-in-part, divisional, renewal or substitute thereof, and as to letters patent any reissue, re-examination, or extension thereof, and for litigation regarding, or for the purpose of protecting title and to the said invention, the United States application for patent, or Letters Patent therefor, and to testify in support thereof, for the benefit of Assignee without further or other compensation than that above set forth;

ASSIGNMENT

Assignor hereby covenants that no assignment, sale, license, agreement or encumbrance has been or will be entered into which would conflict with this Assignment; and

Assignor hereby requests the United States Patent and Trademark Office to issue the Letters Patent of the United States of America to Assignee, and requests that any official of any country or countries foreign to the United States, whose duty it is to issue or grant patents and applications as aforesaid, to issue the Letters Patent, Utility Model Registration or other similar right to Assignee.

The undersigned hereby grant(s) the Assignee or its attorneys or agents to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

He DONG

Witness

Dated

Dated


Yiming ZHAO


Witness

Dated

Dated

Yu LU

Witness

Dated

Dated

ASSIGNMENT

WHEREAS, the undersigned, hereinafter referred to collectively as Assignor, has invented:

IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY

for which Assignor is about to make or has made United States or International application for patent

- (a) ☐ executed on even date preparatory to filing (each inventor should sign this Assignment on the same day as he/she signs the Declaration and Power of Attorney);
- (b) ☐ executed on _____, _____, _____; or
- (c) ☒ filed on October 13, 2023, and assigned PCT Application No. PCT/CN2023/124461; and

WHEREAS, **BeiGene Switzerland GmbH**, having the address of Aeschengraben 27, 4051 Basel, Switzerland, hereinafter referred to as Assignee, is desirous of acquiring all right, title, and interest therein:

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy whereof is hereby acknowledged, Assignor hereby confirms any prior assignment to Assignee, and to the extent that Assignor has not already done so, agrees to assign, and hereby does, sell, assign and transfer unto Assignee and its successors in interest, the full and exclusive right, title and interest in the United States of America and throughout the world, including the right to claim priority under the laws of the United States, the Paris Convention, and any foreign countries, to the inventions as described in the aforesaid application, to the aforesaid application itself, and all divisions, continuations, continuations-in-part, or other applications claiming priority directly or indirectly from the aforesaid application, and any United States or foreign Letters Patent, utility model, or other similar rights which may be granted thereon, including reissues, reexaminations and extensions thereof, and all copyright rights throughout the world in the aforesaid application and the subject matter disclosed therein, these rights, title and interest to be held and enjoyed by Assignee to the full end of the term for which the Letters Patent, utility model, or other similar rights, are granted and any extensions thereof as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made, and the right to sue for, and recover for past infringements of, or liabilities for, any of the rights relating to any of the applications, patents, utility models, or other similar rights, resulting therefrom, and the copyright rights;

Assignor hereby covenants and agrees to execute all instruments or documents required or requested for the making and prosecution of any applications of any type for patent, utility model, or other similar rights, and for copyright, in the United States and in all foreign countries including, but not limited to, any provisional, continuation, continuation-in-part, divisional, renewal or substitute thereof, and as to letters patent any reissue, re-examination, or extension thereof, and for litigation regarding, or for the purpose of protecting title and to the said invention, the United States application for patent, or Letters Patent therefor, and to testify in support thereof, for the benefit of Assignee without further or other compensation than that above set forth;

ASSIGNMENT

Assignor hereby covenants that no assignment, sale, license, agreement or encumbrance has been or will be entered into which would conflict with this Assignment; and

Assignor hereby requests the United States Patent and Trademark Office to issue the Letters Patent of the United States of America to Assignee, and requests that any official of any country or countries foreign to the United States, whose duty it is to issue or grant patents and applications as aforesaid, to issue the Letters Patent, Utility Model Registration or other similar right to Assignee.

The undersigned hereby grant(s) the Assignee or its attorneys or agents to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

He DONG

Witness

Dated

Dated

Yiming Zhao
Yiming ZHAO

Yaqin Yuan
Witness

7.14.2024
Dated

7.14.2024
Dated

Yu LU

Witness

Dated

Dated

ASSIGNMENT

Assignor hereby covenants that no assignment, sale, license, agreement or encumbrance has been or will be entered into which would conflict with this Assignment; and

Assignor hereby requests the United States Patent and Trademark Office to issue the Letters Patent of the United States of America to Assignee, and requests that any official of any country or countries foreign to the United States, whose duty it is to issue or grant patents and applications as aforesaid, to issue the Letters Patent, Utility Model Registration or other similar right to Assignee.

The undersigned hereby grant(s) the Assignee or its attorneys or agents to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

He Dong
He DONG

2024. 7. 17
Dated

Yiming ZHAO

Dated

Yu LU

Dated

Jiao Lin
Witness

2024-7-17
Dated

Witness

Dated

Witness

Dated

ASSIGNMENT

WHEREAS, the undersigned, hereinafter referred to collectively as Assignor, has invented:

IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY

for which Assignor is about to make or has made United States or International application for patent

- (a) ☐ executed on even date preparatory to filing (each inventor should sign this Assignment on the same day as he/she signs the Declaration and Power of Attorney);
- (b) ☐ executed on _____, _____, _____; or
- (c) ☒ filed on **October 11, 2024**, and assigned PCT Application No. **PCT/CN2024/124197**; and

WHEREAS, **BeiGene Switzerland GmbH**, having the address of Aeschengraben 27, 4051 Basel, Switzerland, hereinafter referred to as Assignee, is desirous of acquiring all right, title, and interest therein:

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy whereof is hereby acknowledged, Assignor hereby confirms any prior assignment to Assignee, and to the extent that Assignor has not already done so, agrees to assign, and hereby does, sell, assign and transfer unto Assignee and its successors in interest, the full and exclusive right, title and interest in the United States of America and throughout the world, including the right to claim priority under the laws of the United States, the Paris Convention, and any foreign countries, to the inventions as described in the aforesaid application, to the aforesaid application itself, and all divisions, continuations, continuations-in-part, or other applications claiming priority directly or indirectly from the aforesaid application, and any United States or foreign Letters Patent, utility model, or other similar rights which may be granted thereon, including reissues, reexaminations and extensions thereof, and all copyright rights throughout the world in the aforesaid application and the subject matter disclosed therein, these rights, title and interest to be held and enjoyed by Assignee to the full end of the term for which the Letters Patent, utility model, or other similar rights, are granted and any extensions thereof as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made, and the right to sue for, and recover for past infringements of, or liabilities for, any of the rights relating to any of the applications, patents, utility models, or other similar rights, resulting therefrom, and the copyright rights;

Assignor hereby covenants and agrees to execute all instruments or documents required or requested for the making and prosecution of any applications of any type for patent, utility model, or other similar rights, and for copyright, in the United States and in all foreign countries including, but not limited to, any provisional, continuation, continuation-in-part, divisional, renewal or substitute thereof, and as to letters patent any reissue, re-examination, or extension thereof, and for litigation regarding, or for the purpose of protecting title and to the said invention, the United States application for patent, or Letters Patent therefor, and to testify in support thereof, for the benefit of Assignee without further or other compensation than that above set forth;

Confidential

ASSIGNMENT

Assignor hereby covenants that no assignment, sale, license, agreement or encumbrance has been or will be entered into which would conflict with this Assignment; and

Assignor hereby requests the United States Patent and Trademark Office to issue the Letters Patent of the United States of America to Assignee, and requests that any official of any country or countries foreign to the United States, whose duty it is to issue or grant patents and applications as aforesaid, to issue the Letters Patent, Utility Model Registration or other similar right to Assignee.

The undersigned hereby grant(s) the Assignee or its attorneys or agents to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

He Dong
He DONG

3/12/2025
Dated

Jiao Lin
Witness

3/12/2025
Dated

Yiming Zhao
Yiming ZHAO

3/12/2025
Dated

AO Yu
Witness

3/12/2025
Dated

Yu LU
Yu LU

3/12/2025
Dated

Guomei Wu
Witness

3/12/2025
Dated

CONFIRMATORY PATENT ASSIGNMENT

This Confirmatory Patent Assignment (this "Assignment") is entered into as of the last date noted below, by and between **BeOne Medicines I GmbH (formerly BeiGene Switzerland GmbH)** (hereinafter "**ASSIGNOR**"), a Swiss company having a business address of Aeschengraben 27, 4051 Basel, Switzerland; and **BeOne Guangzhou Biologics Manufacturing Co., Ltd. (formerly BeiGene Guangzhou Biologics Manufacturing Co., Ltd.)**, a corporation having its principal place of business at No. 83 South Kangyao Road, Huangpu District, Guangzhou, Guangdong 510555, P.R. China (hereinafter "**ASSIGNEE**"). Assignor and Assignee are collectively referred to as the "Parties" and each is individually referred to as a "Party."


WHEREAS, pursuant to Intellectual Property Transfer Agreements ("Prior Agreements"), Assignor assigned, transferred, and conveyed, in the country of the mainland of the People's Republic of China (hereinafter, "China"), all of its right, title and interest in and to, *inter alia*, (i) all of the patents and patent applications identified on **Exhibit A** of this Assignment (the "Patents") to Assignee, (ii) in China, the right, title and interest in and to any and all divisional, continuation, substitute or reissue applications pertaining to the Patents, (iii) in China, patents applied for or granted pertaining to the Patents, and (iv) in China, the right to sue and collect past damages in connection with the Patents (i-iv collectively referred to as the "Patent Rights"), and Assignee agreed to accept the Patent Rights. For clarity, China does not include any of Hong Kong, Macau, or Taiwan.

NOW, THEREFORE, with acknowledgement by the Parties of the receipt and exchange of valuable and sufficient consideration associated with the Prior Agreements, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1. To confirm the above-noted assignments pursuant to the Prior Agreements, as of December 6, 2024, *nunc pro tunc*, Assignor hereby assigns, transfers, conveys and sets over to the Assignee, its successors and assigns, and Assignee hereby accepts, all right, title and interest, in and to the Patent Rights, to have and to hold the same, unto Assignee for its own use and enjoyment and for the use and enjoyment of its successors and assigns, for the full term or terms of all such rights. The assignment of the Patents shall include the right to file patent applications under the laws of China, including the right to claim the benefits of the International Convention for such applications.
2. Assignor hereby authorizes and requests that any official of China whose duty it is to issue or grant patents and applications, to issue any and all patents within the Patent Rights to Assignee as the owner thereof.
3. Assignor hereby agrees, without further consideration and without expense to the Assignor, to sign all documents and to perform all other lawful acts which the Assignee may reasonably request to make this Assignment of the Patent Rights fully effective.
4. This Assignment shall be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and permitted assigns.
5. This Assignment may be executed and delivered (including electronically) in one or more counterparts, and by the Parties in separate counterparts, each of which when executed shall be deemed to be an original, but when taken together shall constitute one and the same agreement.

IN WITNESS WHEREOF, Assignor and Assignee has each caused this Assignment to be duly signed on its behalf.

BeOne Medicines I GmbH (ASSIGNOR)



Name: Giancarlo Benelli

Title: Senior Vice President, Commercial

Date: July9, 2025

**BeOne Guangzhou Biologics Manufacturing Co., Ltd.
(ASSIGNEE)**

Name:

Title:

Date:

BeOne Medicines I GmbH (ASSIGNOR)

Name:

Title:

Date:

**BeOne Guangzhou Biologics Manufacturing Co., Ltd.
(ASSIGNEE)**

Qing Wang

Name: Qing Wang

Title: IP Counsel

Date: June 30, 2025

EXHIBIT A

Country	Application No.	Application Date	Patent No.	Grant Date	Title	Status
WO	PCT/CN2024/076654	2024/2/7	/	/	PREPARATION METHODS FOR A HIGHLY CONCENTRATED PD1 ANTIBODY SOLUTION BY APPLYING SINGLE-PASS TANGENTIAL FLOW FILTRATION (SPTFF)	Published
WO	PCT/CN2024/079594	2024/3/1	/	/	CD16A ANTIBODIES AND METHODS OF USE	Published
WO	PCT/CN2024/079596	2024/3/1	/	/	MUC1 ANTIBODIES AND METHODS OF USE	Published
WO	PCT/IB2024/052794	2024/3/22	/	/	BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF	Published
WO	PCT/IB2024/052126	2024/3/5	/	/	ANTI-CD3 MULTISPECIFIC ANTIBODIES AND METHODS OF USE	Published
WO	PCT/IB2024/052124	2024/3/5	/	/	ANTI-CLDN6 AND ANTI-CD3 MULTISPECIFIC ANTIBODIES AND METHODS OF USE	Published
WO	PCT/IB2024/052127	2024/3/5	/	/	ANTI-CLDN6 ANTIBODIES AND METHODS OF USE	Published
WO	PCT/CN2024/081840	2024/3/15	/	/	ANTI-B7H3 ANTIBODIES AND METHODS OF USE	Published
WO	PCT/CN2024/087465	2024/4/12	/	/	TARGETED PYRROLOBENZODIAZAPINE CONJUGATES	Published
WO	PCT/CN2024/112302	2024/8/15	/	/	TREATMENT OF LUNG CANCER WITH ANTI-PD-1 AND CHEMOTHERAPY	Published
WO	PCT/IB2024/057756	2024/8/9	/	/	BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF	Published
WO	PCT/IB2024/057757	2024/8/9	/	/	BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF	Published
WO	PCT/IB2024/058665	2024/9/5	/	/	CIRCULAR RNA AND PREPARATION METHODS THEREOF	Published
WO	PCT/CN2024/124197	2024/10/11	/	/	IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY	Published
WO	PCT/IB2024/059994	2024/10/11	/	/	ANTI-PD-1-BASED TREATMENT BEFORE AND AFTER SURGERY	Published